NCT00158782 - Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 28, 2004

Primary Completion Date

August 21, 2007

Study Completion Date

August 21, 2007

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

GW786034

GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.

DRUG

lapatinib

Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.

Trial Locations (2)

27705

GSK Investigational Site, Durham

3075 EA

GSK Investigational Site, Rotterdam